Abstract | BACKGROUND: OBJECTIVES: To determine whether or not patients with exacerbations have elevated serum SP-D levels compared with asymptomatic controls, stable disease. STUDY DESIGN: case control study. METHODS: We measured serum SP-D levels from patients with stable COPD (n= 14), patients experiencing acute exacerbations (n=13) and in control subjects (n=54) using a specific immunoassay and compared the levels using analysis of variance. RESULTS: Serum SP-D levels were significantly increased in patients who experienced an acute exacerbation (227 +/- 120 ng/mL) compared to patients with stable disease (151 +/- 83 ng/mL) or control subjects (128 +/- 65 ng/mL; p=0.003). Serum SP-D levels were also found to be inversely related to various lung function parameters including FEV<formula>_{1}</formula>/FVC% predicted. CONCLUSIONS: Our study suggests that serum SP-D levels are increased in patients during exacerbations and may be a potential diagnostic biomarker for COPD exacerbations.
|
Authors | Tania Ahmed Shakoori, Don D Sin, Farkhanda Ghafoor, Saira Bashir, S Nazim Hussain Bokhari |
Journal | Disease markers
(Dis Markers)
Vol. 27
Issue 6
Pg. 287-94
( 2009)
ISSN: 1875-8630 [Electronic] United States |
PMID | 20075511
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Pulmonary Surfactant-Associated Protein D
|
Topics |
- Acute Disease
- Adult
- Aged
- Biomarkers
(blood)
- Case-Control Studies
- Disease Progression
- Dyspnea
(blood, pathology)
- Forced Expiratory Volume
- Humans
- Lung
(metabolism, physiopathology)
- Middle Aged
- Pulmonary Disease, Chronic Obstructive
(blood, pathology)
- Pulmonary Surfactant-Associated Protein D
(blood)
|